Fortune J Health Sci 2020; 3 (2): 110-121 DOI: 10.26502/fjhs012 Fortune Journal of Health Sciences Vol. 3 No. 2 - September 2020 110 Original Article Spectrum of Bleeding Disorders In Pakistan: A Cross-Sectional Study Muhammad Sohaib Asghar 1 * , Ayesha Asghar 2 , Fatima Asghar 3 , Mohammed Akram 4 1 Resident Physician of Internal Medicine, Dow University Hospital, Dow University of Health Sciences, Karachi, Pakistan 2 Graduate, Masters of Science in Biochemistry, Karachi University, Karachi, Pakistan 3 Graduate, BDS (Dentistry), Dow International Dental College, Karachi, Pakistan 4 Intern of Internal Medicine at Liaquat National Hospital & Medical College, Karachi, Pakistan *Corresponding Author: Muhammad Sohaib Asghar, Resident Physician of Internal Medicine, Dow University Hospital, Dow University of Health Sciences, Karachi, Pakistan, Tel: +92334-3013947; E-mail: sohaib_asghar123@yahoo.com Received: 13 July 2020; Accepted: 23 July 2020; Published: 31 July 2020 Citation: Muhammad Sohaib Asghar, Ayesha Asghar, Fatima Asghar, Mohammed Akram. Spectrum of Bleeding Disorders In Pakistan: A Cross-Sectional Study. Fortune Journal of Health Sciences 3 (2020): 110-121. Abstract This is a cross-sectional study conducted to determine the frequency and spectrum of bleeding disorders in different regions of Pakistan and to improve facilities to cure them. Samples were collected from different regions of Pakistan. There bleeding presentation and history of the family were recorded. 435 patients were selected from the different regions of Pakistan; 318 male (73%) and 117 female (26%). Laboratory analysis included Prothrombin time, Activated partial thromboplastin time, Bleeding time, platelet counts and fibrinogen assay were performed. According to their results, vWF:Ag, vWF:RCo, inhibitor screening, Bethesda test, urea clot solubility test, and platelet aggregation test were performed to diagnosed bleeding disorders in patients. Out of 435 patients, 283 constitute CBD, 80 diagnosed with RBD, and 72 remain undiagnosed. Patients diagnosed with 52% hemophilia A, 1.4% with its inhibitor, 8.4% with hemophilia B, 0.35% with its inhibitor, 3.88% with VWD, 33.5%with its type III. A rare bleeding disorder is diagnosed in 80